How to Decide Exactly Where to Get Fillers and Botox
Your forehead isn't the only spot you can get an injectable. Here's what you need to know about filler and Botox injection sites — both well-established and newly available, according to Shape.
Category: Injectibles
Injectibles
Popular
Injectibles
Latest
Revance Replaces Lidocaine with Mepivacaine in RHA Filler Line
Revance announces the U.S. launch of the Teoxane RHA Collection with mepivacaine, replacing lidocaine as the anesthetic in its dermal filler products.
All
Latest
Study Highlights Decision-Support Tool for Breast Reconstruction Choices
Findings suggest that tools designed to elicit patient values can improve communication and support African American women in choosing between implant-based and autologous reconstruction after mastectomy.
Health Canada Approves Radiesse for Décolleté Wrinkles
Regulatory approval allows clinicians to use the biostimulatory filler to treat moderate wrinkles in the chest area.
Read More
Where Non-Surgical Aesthetic Spending Is Headed: Inside the $17.5 Billion Aesthetic Shift
Guidepoint Qsight’s Erik Haines breaks down the drivers behind 2024’s $17.5 billion in non-surgical aesthetic spending and what it signals for the future of the industry.
Read More
How Evolysse Could Change the HA Filler Market: Insights from Dr Rami Batniji
Dr Rami Batniji discusses how Evolysse’s cold technology manufacturing process may offer clinical advantages over traditional hyaluronic acid fillers.
Read More
Understanding the Rise in Male Facial Plastic Surgery: Insights from AAFPRS President Patrick Byrne
AAFPRS President Dr. Patrick Byrne discusses the growing interest in facial cosmetic procedures among male patients and how private practices can adapt to meet their evolving needs.
Read More
New Revanesse Renew+ Skin-boosting Injection Debuts in Canada
The product is designed to provide long-lasting hydration to improve skin quality from the inside out.
Read More
New Short-Term Botox-Like Treatment Moves Closer to FDA Review
The neurotoxin is characterized by a rapid onset of action as early as eight hours after administration and a shorter duration of effect of two to three weeks.
Read More
Evolysse Form and Smooth Injectable HA Gels Hit Market
Evolus launched its Evolysse Form and Evolysse Smooth injectable HA gels on April 18, following a national webcast and early access program involving over 1,000 aesthetic practices.
Read More
A New Player in the Toxin Market: Dr Donald Yoo on Letybo’s U.S. Prospects
Beverly Hills facial plastic surgeon Donald Yoo, MD, shares insights on Letybo’s clinical performance, its potential in the U.S. market, and how platforms like Persana are changing the injectable landscape.
Read More
CaHA Injectable for Facial Use Gains Regulatory Approval in China
The approval makes it the first calcium hydroxylapatite microsphere injectable product approved in China for facial soft tissue augmentation, according to the company.
Read More
Galderma to Share New Data on Injectables and Weight Loss–Related Facial Changes
The company will present findings on Relfydess, Sculptra, and Restylane, along with results from an international survey on aesthetic impacts of medication-driven weight loss.
Read More
Prollenium Launches PACE Academy for Advanced Medical Aesthetics Training
Prollenium’s PACE Academy, in partnership with Harley Academy, offers advanced medical aesthetics training with innovative tools.
Read More
Evolus Announces FDA Approval of Two Injectable Hyaluronic Acid Gels
Evolus secures FDA approval for Evolysse Form and Evolysse Smooth, set to launch in Q2 2025 with advanced Cold-X technology.
Read More
FDA Approves Two New Hyaluronic Acid Fillers
One newly approved HA filler showed statistical superiority to Restylane-L at all measured time points over 12 months, while the other was superior at six and nine months despite 20% more Restylane-L being used.
Read More
New Data Confirms Long-Term Safety of RelabotulinumtoxinA
Baldo Scassellati Sforzolini, MD, PhD, MBA, Galderma’s global head of research, recently presented data on RelabotulinumtoxinA, a six-month neuromodulator for wrinkles. The READY-4 trial confirms its safety and efficacy, supported by PEARL Technology across diverse groups. Here, Sforzolini shares his findings.
Read More
Climate Impacts Botox Efficacy: More Needed in High-Sun Areas
Patients living in “high-sun” climates may require higher doses of Botox to achieve good results in the cosmetic treatment of facial lines and wrinkles, reports a study in the July issue of Plastic and Reconstructive Surgery.
Read More